Editas Medicine, Inc.·4

Mar 4, 4:49 PM ET

Parison Amy 4

4 · Editas Medicine, Inc. · Filed Mar 4, 2026

Insider Transaction Report

Form 4
Period: 2026-03-03
Parison Amy
SVP, Chief Financial Officer
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-03-03$2.02/sh474$95715,434 total
Footnotes (2)
  • [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
  • [F2]This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Signature
/s/ Amy Parison|2026-03-04

Documents

1 file
  • 4
    wk-form4_1772660958.xmlPrimary

    FORM 4